Andere Kunden interessierten sich auch für
![Rare Respiratory Diseases]( "Rare Respiratory Diseases")
Rare Respiratory Diseases73,99 €![Inhalations in the Treatment of Diseases of the Respiratory Passages: Particularly As Affected by the Use of Atomised Fluids]( "Inhalations in the Treatment of Diseases of the Respiratory Passages: Particularly As Affected by the Use of Atomised Fluids")
Inhalations in the Treatment of Diseases of the Respiratory Passages: Particularly As Affected by the Use of Atomised Fluids29,99 €![Innovative Technology Based Interventions for Psychological Treatment of Common Mental Disorders]( "Innovative Technology Based Interventions for Psychological Treatment of Common Mental Disorders")
Innovative Technology Based Interventions for Psychological Treatment of Common Mental Disorders58,99 €![Surgical Treatment of Pancreatic Ductal Adenocarcinoma]( "Surgical Treatment of Pancreatic Ductal Adenocarcinoma")
Surgical Treatment of Pancreatic Ductal Adenocarcinoma73,99 €![Psychoneurobiology Research and Personalized Treatment of Schizophrenia]( "Psychoneurobiology Research and Personalized Treatment of Schizophrenia")
Psychoneurobiology Research and Personalized Treatment of Schizophrenia59,99 €![Assessment & Treatment of Addictions]( "Assessment & Treatment of Addictions")
Assessment & Treatment of Addictions62,99 €![Clinical Advances in Cerebral Aneurysm Treatment]( "Clinical Advances in Cerebral Aneurysm Treatment")
Clinical Advances in Cerebral Aneurysm Treatment64,99 €
Respiratory infections are conventionally treated with oral or intravenous antimicrobials (antivirals, antibiotics, and antifungals). However, these routes of administration are not ideal because the required drugs are systemically delivered rather than being targeted to the respiratory tract. Higher doses may also be needed to achieve sufficient drug concentrations in the lungs, which may consequently increase the risk of adverse effects. On the other hand, the drugs can be efficiently delivered into the airways as inhaled aerosols. Lower doses can then be used to attain relatively high local concentrations. There are specific challenges to the development of inhaled formulations, such as the optimisation of their physicochemical stability and aerosol performance. In addition, antimicrobial resistance is an urgent global public health issue. Novel strategies are required to overcome these problems. The papers in this reprint focus on recent advancements in inhaled antimicrobials and vaccines, including those for viral (SARS¿CoV¿2), bacterial (Mycobacterium tuberculosis, Mycoplasma pneumoniae, Acinetobacter baumanii), and fungal infections (moulds).